Hemispherx Biopharma Announces Initial Test Results in Biosecurity/Biodefense Arena

PHILADELPHIA, Sept. 12, 2013 (GLOBE NEWSWIRE) -- Chairman and CEO, William A. Carter, M.D. of Hemispherx Biopharma (NYSE MKT:HEB) announced at the Rodman and Renshaw Conference in New York City, NY on September 9, 2013, a major new initiative in the BioSecurity field involving both Alferon N Injection® and Ampligen®. Alferon N Injection® is a multi-species, natural interferon; the only natural interferon approved for sale in the U.S. Ampligen® is a dsRNA experimental therapeutic that acts as a TLR 3 activator.

Help employers find you! Check out all the jobs and post your resume.